A comparative study of interaction of ibuprofen with biocompatible polymers

Thermodynamic Changes Induced by Intermolecular Interaction Between Ibuprofen and Chitosan: Effect on Crystal Habit, Solubility and In Vitro Release Kinetics of Ibuprofen

“…In essence, the concentration of the drug should be high enough to ensure therapeutic effect however excessive doses should be avoided because this may result in potentially harmful side effects. In order to improve the biopharmaceutical properties of ibuprofen, amphiphilic drug-biocompatible polymer conjugates have been the focus of formulation research in the recent past (5,6,8,14). Literature is replete with research reports on chitosan-based polyelectrolyte complexes with oppositely charged natural and synthetic polyelectrolytes however the general problem of aqueous association of poorly soluble amphiphilic drug and poorly water soluble polymers remain unresolved.…”

Polymer-Amphiphile Interactions: An Overview

“…The CP values of HPMC decreased linearly with the increase of salt concentration in the presence of IMP and PMZ, whereas in their absence the effect was negligible. The authors [91] have also reported interaction of the non-steroidal anti-inflammatory drug, IBF, with various biocompatible polymers viz. PVP, polyethylene glycol (PEG), HPMC, hydroxyethyl cellulose (HEC), sodium carboxymethyl cellulose (NaCMC), dextran sulphate (DxS), hydroxyethyl cellulose ethoxylate (HECEQ).…”

“…Strength of interactions between the drugs IMP/PMT and the polymers was dependent on the nature and concentration of the latter. Recently, it has been reported that the anionic IBF interacted more strongly with the cationic polymers than the nonionic ones whereas the anionic polymers showed least interaction [102]. Influence of six polymers viz.…”

Ultrasonic atomization and polyelectrolyte complexation to produce gastroresistant shell–core microparticles

“…The better encapsulation obtained with the chosen E100 concentration (a concentration higher than 0.5% w/v gave a too much viscous, not practical to use, solution) can be explained on the bases of the availability of binding sites: when the amount of macromolecule increases, there is an increase in the charged binding sites accessible to drug, therefore, larger amount of the drug results bound to the macromolecule. 47 The encapsulation efficiency kept unchanged after the two stages complexation in BATCH C microparticles (EE about 74%, loading: 2.75%) reasonably because IND was already "blocked" in the polymeric network during the first complexation. It is worth to note that the efficiency of the novel process, as defined in eq.…”

“…47 As reported in previous works 48,49 the encapsulation efficiency was subjected to several factors, mainly drug molecular weight and solubility and polymeric network mesh-size (PNMS), which play a crucial role on drug losses due to diffusive transport phenomena occurring during reticulation stage of microparticles production. Adding a polymeric mesh-size reducer ingredient (such as the Pluronic) has demonstrated that better encapsulation efficiency can be allowed 50 but this strategy, in general, must be evaluated on the bases of drug an polymer features.…”